True medical - Company finances
|
EUR
|
2022
From: 2022-04-26
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 0 | - | 55,700 | 202,939 |
| Profit before tax | - | - | - | - |
| Net profit | 0 | 0 | -46,489 | 56,068 |
| Equity | 2,500 | 2,500 | -43,989 | 12,079 |
| Liabilities | 0 | 0 | 82,318 | 108,889 |
| Non-current assets | 0 | 0 | 13,894 | 10,845 |
| Current assets | 2,500 | 2,500 | 24,435 | 110,123 |
| Total assets | 2,500 | 2,500 | 38,329 | 120,968 |
|
Taxes paid
|
||||
| STI taxes | - | 1,418 | 5,675 | 13,457 |
| Social insurance contributions | - | - | 8,702 | 14,749 |
|
Financial indicators
|
||||
| Revenue change y/y | - | - | - | +264.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.0% | 0.0% | -121.3% | 46.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.0% | 0.0% | - | 464.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | -83.5% | 27.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 9.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | 7,427 | 15,511 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
True medical - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-10-16 | 2024-10-20 | 111.88 |
| 2024-05-16 | 2024-05-19 | 615.60 |
| 2024-02-28 | 2024-03-03 | 137.50 |
| 2024-02-20 | 2024-02-27 | 328.15 |
| 2024-01-26 | 2024-01-30 | 1.78 |
| 2024-01-23 | 2024-01-25 | 329.93 |
| 2024-01-22 | 2024-01-22 | 328.15 |
| 2023-11-24 | 2023-12-04 | 4.19 |
| 2023-11-17 | 2023-11-23 | 332.33 |
| 2023-10-27 | 2023-11-16 | 4.19 |
| 2023-10-25 | 2023-10-26 | 176.09 |
| 2023-10-18 | 2023-10-24 | 171.90 |
| 2023-09-21 | 2023-09-28 | 4.82 |
| 2023-08-22 | 2023-09-20 | 5.69 |
| 2023-07-27 | 2023-08-20 | 260.96 |
| 2023-07-26 | 2023-07-26 | 334.69 |
| 2023-07-24 | 2023-07-25 | 334.90 |
| 2023-07-20 | 2023-07-23 | 328.13 |
| 2023-07-19 | 2023-07-19 | 653.78 |
| 2023-06-27 | 2023-07-18 | 325.65 |
| 2023-06-20 | 2023-06-26 | 328.15 |
| 2023-06-16 | 2023-06-19 | 656.40 |
| 2023-05-17 | 2023-06-15 | 328.25 |
| 2023-05-02 | 2023-05-16 | 0.10 |
| 2023-04-27 | 2023-04-28 | 0.10 |
| 2023-04-25 | 2023-04-25 | 0.10 |
| 2023-04-18 | 2023-04-18 | 328.15 |
True medical - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-08-05 | 2026-08-13 | 1093.09 |
| 2026-07-02 | 2026-07-07 | 0.75 |
| 2026-06-18 | 2026-07-01 | 168.64 |
| 2026-04-14 | 2026-04-15 | 139.66 |
| 2026-02-03 | 2026-02-16 | 735.91 |
| 2026-01-30 | 2026-02-02 | 723.57 |
| 2026-01-18 | 2026-01-29 | 716.68 |
| 2026-01-11 | 2026-01-15 | 233.62 |
| 2025-08-10 | 2025-08-14 | 324.22 |
| 2025-07-12 | 2025-07-20 | 534.06 |
| 2025-03-15 | 2025-03-16 | 148.1 |
| 2025-01-16 | 2025-02-14 | 1.9 |
| 2025-01-10 | 2025-01-15 | 940.54 |
| 2025-01-09 | 2025-01-09 | 2.82 |
| 2025-01-01 | 2025-01-08 | 69.97 |
| 2024-12-31 | 2024-12-31 | 69.95 |
| 2024-12-24 | 2024-12-30 | 69.81 |
| 2024-12-18 | 2024-12-23 | 69.69 |
| 2024-12-17 | 2024-12-17 | 67.29 |
| 2024-12-14 | 2024-12-16 | 645.29 |
| 2024-12-01 | 2024-12-13 | 2.67 |
| 2024-11-20 | 2024-11-30 | 3.28 |
| 2024-11-17 | 2024-11-19 | 134.98 |
| 2024-10-12 | 2024-10-15 | 781.54 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
True medical, UAB (code 306069586) is a Private Limited Liability Company engaged in medical specialists activities. In the latest financial year, 2025, the company generated revenue of €202.9K and net profit of €56.1K, which corresponds to a profit margin of 27.6%. Revenue increased sharply from €55.7K in 2024, while the company moved from a net loss of €46.5K to a solid profit in 2025. This shows a clear turnaround in operating performance over the two-year period.
At the end of 2025, total assets stood at €121.0K, supported by €10.8K of long-term assets and €110.1K of short-term assets. Equity was €12.1K and liabilities €108.9K, indicating a highly leveraged balance sheet and a low equity ratio of 10.0%. Asset turnover was 1.68x, suggesting that assets were used actively to generate revenue. Revenue per employee was €15.6K and profit per employee was €4.3K. Return on assets was 46.4%, while return on equity was elevated due to the small equity base.
At the end of 2025, total assets stood at €121.0K, supported by €10.8K of long-term assets and €110.1K of short-term assets. Equity was €12.1K and liabilities €108.9K, indicating a highly leveraged balance sheet and a low equity ratio of 10.0%. Asset turnover was 1.68x, suggesting that assets were used actively to generate revenue. Revenue per employee was €15.6K and profit per employee was €4.3K. Return on assets was 46.4%, while return on equity was elevated due to the small equity base.